Butterfly Network, Inc. Q2 2026 Earnings Call Summary

Moby Intelligence

Fri, July 31, 2026 at 5:34 AM GMT+3 3 min read

Butterfly Network, Inc. Q2 2026 Earnings Call Summary - Moby

Strategic Performance Drivers

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Performance beat was driven by the 'flywheel' effect of three emerging growth engines: Point-of-Care Ultrasound (POCUS), Home and Community Care, and Embedded partnerships.
The Embedded business saw a 439% revenue increase, primarily attributed to the Midjourney partnership and the growing market recognition of semiconductor-based imaging's potential.
Core POCUS growth was bolstered by a shift toward enterprise-level software deals, with the Compass AI pipeline increasing five times since last year.
Management attributes record gross margins of 71% to a favorable revenue mix, specifically the high-margin contributions from the Butterfly Embedded segment.
Strategic positioning in medical education reached a milestone with 80% of U.S. medical schools now using Butterfly, shifting from small device placements to full one-to-one ultrasound curricula.
International revenue declined 14% due to a difficult year-over-year comparison against the iQ3 launch and several large deals shifting into the third quarter.

Outlook and Strategic Roadmap

Full-year 2026 revenue guidance was raised to $119 million-$123 million, reflecting confidence in the commercialization of Home and Community Care and Embedded milestones.
The next-generation probe, built on the P5.1 chip, is on track for a Q1 2027 launch, aiming to deliver harmonic imaging that exceeds the performance of traditional PZT handheld competitors.
Management expects to enter the multi-billion dollar ultrasound cart market in late 2027 with the launch of iQ Station, leveraging existing hospital capital budgets.
The Home and Community Care segment is scheduled to begin its first commercial implementation on October 1st, with revenue expected to materialize in Q4 2026.
Apollo chip deliveries to Midjourney are scheduled for late 2027 or early 2028, coinciding with the transition of the fourth-generation chip from research to development.

Operational Risks and Strategic Investments

The VCOM partnership included preferred pricing for legacy iQ+ inventory to secure a long-term, $10 million commitment to the iQ3 platform, resulting in a 12% decrease in ASP for the quarter.
Butterfly received provisional authorization for the full VA system and expects full FedRAMP certification in Q3, opening the U.S. government as a major purchasing channel.
Macroeconomic headwinds, including Middle East conflicts and AI-driven supply chain shortages, have had only minor impacts to date but remain under close monitoring.
The company is firemalling its Embedded organization from core development teams to ensure partnership scaling does not distract from the core POCUS business.

Q&A Session Summary

Embedded revenue cadence and visibility over the next 24 months

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management expects Embedded revenue to maintain a cadence of approximately $7 million to $8 million per quarter, with fluctuations based on milestone achievements.
While current revenue includes NRE payments and license fees, the 'big pops' in revenue are expected when partners transition to full commercialization and chip-sharing models.

Scalability of the Embedded partnership model beyond 11 partners

Management sees no practical limit to the number of partnerships because they utilize a standardized semiconductor platform rather than custom chips for each client.
The business model is evolving from a 'job shop' into a scalable software platform where partners pay for development work, hardware, and eventually, high-volume chip purchases.

Revenue model and milestones for Home and Community Care

The revenue model includes a fixed fee based on the size of the managed patient population plus a variable fee for every scan performed.
Success will be measured by the reduction in hospital readmission rates for congestive heart failure patients, with potential for Butterfly to share in the cost savings generated for at-risk providers.

Competitive positioning of the P5.1 chip versus traditional ultrasound

Management claims the P5.1 chip will deliver better cardiac images than the handheld devices of the largest imaging companies, potentially making traditional PZT technology obsolete.
The strategy is to enter the $1.6 billion to $2 billion POCUS cart market with a superior, networked product that avoids the high cost of 'market development' by tapping into existing demand.